Show simple item record

dc.contributor.authorAttard, Gen_US
dc.contributor.authorAntonarakis, ESen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2016-11-23T14:41:25Z
dc.date.issued2016-12en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/27804988en_US
dc.identifiernrurol.2016.212en_US
dc.identifier.citationNat Rev Urol, 2016, 13 (12), pp. 697 - 698en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/267
dc.identifier.eissn1759-4820en_US
dc.identifier.doi10.1038/nrurol.2016.212en_US
dc.format.extent697 - 698en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectAndrostenesen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectDrug Resistance, Neoplasmen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectPhenylthiohydantoinen_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectProstatic Neoplasms, Castration-Resistanten_US
dc.subjectReceptors, Androgenen_US
dc.titleProstate cancer: AR aberrations and resistance to abiraterone or enzalutamide.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/nrurol.2016.212en_US
rioxxterms.licenseref.startdate2016-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfNat Rev Urolen_US
pubs.declined2016-11-10T14:09:24.237+0000
pubs.deleted2016-11-10T14:09:24.237+0000
pubs.issue12en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance
pubs.publication-statusPublisheden_US
pubs.volume13en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTreatment Resistanceen_US
dc.contributor.icrauthorAttard, Gerhardten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record